Designing metal chelates of halogenated sulfonamide Schiff bases as potent nonplatinum anticancer drugs using spectroscopic, molecular docking and biological studies

Rehab M. I. Elsamra, Mamdouh S. Masoud & Ahmed M. Ramadan

In this contribution, five Ni(II) complexes have been synthesized from sulfonamide-based Schiff bases (SB1–SB5) that comprise bromo or iodo substituents in the salicylidene moiety. The chemical structures of these compounds were extensively elucidated by different analytical and physicochemical studies. All ligands act as bidentate chelators with ON binding mode yielding octahedral, square planar, or tetrahedral geometries. The phenolic OH at δ 12.80 ppm in the free Schiff base SB2 vanishes in the 1H NMRspectrum of diamagnetic complex [Ni(SB2–H)2] favoring the OH deprotonation prior to the chelation with Ni(II) ion. The appearance of twin molecular ion peaks ([M − 1]+ and [M + 1]+) is due to the presence of bromine isotopes (79Br and 81Br) in the mass spectra of most cases. Also, the thermal decomposition stages of all complexes confirmed their high thermal stability and ended with the formation of NiO residue of mass 6.42% to 14.18%. Besides, antimicrobial activity and cytotoxicity of the ligands and some selected complexes were evaluated. Among the ligands, SB4 showed superior antimicrobial efficacy with MIC values of 0.46, 7.54, and 0.95 µM against B. subtilis, E. coli, and A. fumigatus strains, respectively. The consortium of different substituents as two bromine atoms either at positions 3 and/or 5 on the phenyl ring and a thiazole ring is one of the reasons behind the recorded optimal activity. Moreover, there is a good correlation between the cytotoxicity screening (IC50) and molecular docking simulation outcomes that predicted a strong binding of SB2 (16.0 μM), SB4 (18.8 μM), and SB5 (6.32 μM) to the breast cancer protein (3s7s). Additionally, [Ni(SB4–H)2] (4.33 μM) has nearly fourfold potency in comparison with cisplatin (19.0 μM) against breast carcinoma cells (MCF-7) and is highly recommended as a promising, potent, as well as low-cost non-platinum antiproliferative agent after further drug authorization processes.

Conjugated heterocyclic systems containing nitrogen, oxygen, and sulfur atoms in their structures have long been known for their diverse biological actions. The activity of these heterocyclic compounds against wide varieties of pathogens increases especially when introduced in the form of metal complexes. Transition metal complexes of Schiff bases derived from sulfa drugs are among systems that have been reported extensively for their pronounced medicinal performance. Most of the sulfa drugs exhibit a bacteriostatic effect by preventing cell division through the inhibition of the dihydropteroate synthase enzyme that is essential in the proteins and nucleic acids formation in bacterial cells. Crucially, coupling of Schiff bases-sulfonamide moieties with halogen substituents could enhance the therapeutic efficiency including antimicrobial, antitumor, and antiviral activities. Halogens, such as bromine and iodine have a prominent ability to interact with electron donor atoms due to their electron-withdrawing property that generates σ-hole, positive electrostatic potential, along the halogen bond. They can effectively form stable donor–acceptor bonds with the surrounding molecules such as the electron-rich sites of the adjacent amino acids. This enhances the binding affinity to certain proteins.
Clearly, the mutual existence of different units of hetero atoms, halogens, and metal ions in one combined structure is particularly important because of the role played by each entity. Such combined structure creates unequal electron density distribution with different electrophilic and nucleophilic regions on the surface of the molecules which increases the chance of chelation with proteins and provides a wide range of chemical and biological practices. Although there are massive investigations on antipathogenic agents with different functional groups and structures to find more effective and less toxic drugs, the rapid evolution of research is still challenging the need to overcome the quick development of drug-resistant microbes. Besides, Schiff bases have been recognized as catalysts, corrosion inhibitors, and efficient polymer stabilizers. The diversity of the bioinorganic applications of Schiff bases is stemmed from the fact that this class of compounds possesses a high complexing ability through the azomethine group and neighboring donor atoms in a polydentate fashion. In consideration of the mentioned observations, the current research is aiming to examine the microbial and tumor inhibition activities of newly synthesized nickel (II) complexes derived from mono- and di-halogenated Schiff bases bearing the bioactive benzenesulphonamide group. In addition, the structural variations of the investigated ligands and complexes such as different pendant substituents or geometric chelation types are correlated theoretically and experimentally as important parameters accountable for their chemical and biological behaviors.

**Experimental**

**Chemicals, instruments, and computations.** Nickel (II) nitrate hexahydrate salt and 5-bromosalicylaldehyde were obtained from Sigma-Aldrich with high purity (≥ 98%). 3,5-Dihalosubstituted salicylaldehyde (X$_2$C$_6$H$_4$-OH)CHO, where X = Br or I, were prepared following the known methods in the literature. Infrared spectra of the synthesized ligands and their complexes were recorded by FT-IR tensor 37 spectrophotometer in the range 400–4000 cm$^{-1}$. Microanalysis (CHNS) was performed at the microanalytical laboratory, Cairo University. The metal content in each sample was doubly determined by atomic absorption spectrophotometer and by complexometric back titration using standard EDTA solution and Eriochrome black T indicator. Also, the absorption in the UV–Vis region was conducted by the SHIMADZU UV-1800 scanning spectrophotometer in the wavelength range 200–800 nm using dimethylformamide as a solvent. The mass-to-charge ratio of the molecular ions was measured by SHIMADZU mass spectrometer (QP2010 Plus) at an electron energy of 70 eV at Cairo University and by Thermo Scientific GCMS model ISQ et al.-Azhar University, Cairo, Egypt. Thermal decomposition of the complexes was investigated by the thermogravimetric (TGA) as well as the differential thermogravimetric (DTA) techniques using LINSEIS STA PT1000 analyzer under N$_2$ atmosphere as inert gas and a temperature rate of 10 °C/min. The $^1$H NMR and $^{13}$C NMR spectra were studied for the ligands and the diamagnetic complex in a deuterated dimethyl sulfoxide solvent on a 500 MHz spectrometer.

Geometry optimization and structural energy calculations of some selected compounds were computed by density functional theory (DFT) using GAUSSIAN09 software, Version 9.5, and GAUSSVIEW 6.0.16. Hybrid exchange–correlation function (B3LYP) with the basis set Lanl2dz was chosen for the investigated systems. This level of theory (DFT/B3LYP) has been approved as an effective approach to calculate the electronic properties of organic systems containing electronegative atoms, analogous to the present work. True energy minima of the optimized structures were proved by the absence of imaginary vibrational frequencies in the GAUSSIAN output files. A molecular docking study was conducted by the Molecular Operating Environmental module (MOE 2015.10). The 3D structure of the selected protein 3s7s was adopted from the protein data bank. As docking initial steps, the protein structure was set up by removing water molecules and adding hydrogen atoms. Also, a site finder was used for the ligand-binding site prediction. Evaluation of the best binding pose between the investigated ligands and the receptor protein was based on the H-bond length and the scoring energy of the simulated docked complex.

**Antimicrobial and cytotoxicity assessment.** The in vitro biological activity of the synthesized halo-genated Schiff bases and some of their complexes was investigated employing Kirby–Bauer agar diffusion assay against different pathogenic species including Gram-negative bacteria (P. vulgaris & E. coli), Gram-positive bacteria (S. aureus & B. subtilis), and fungi (A. fumigatus & C. albicans) as depicted in the literature. All inhibition zone diameter values in mm were assessed in triplicates for the tested samples. Also, MIC (minimal inhibitory concentration in µg/ml) was determined by the serial dilution method as reported. The activity of the tested compounds was compared to ketoconazole, gentamycin, and ampicillin as reference controls for antifungal and antibacterial potencies.

Besides, the cytotoxicity of some selected synthesized ligands and complexes against human breast carcinoma cell line (MCF-7) and normal human oral epithelial cell (OEC) was evaluated by colorimetric viability assay as reported. All human cancer cell lines were obtained from the VACSERA Tissue Culture Unit, Egypt and the OEC cells (PCS-200-014) were from American Culture Type Collection. Cisplatin was used as a standard reference under the same assay specifications. The biological measurements were carried out et al.-Azhar University, Cairo, Egypt.

**Synthesis of Schiff bases (SB$_1$–SB$_3$).** Mono- or dihalosubstituted salicylaldehyde (10 mmol) was dissolved in ethanol and then added to equimolar of a primary amine solution, sulfanilamide (10 mmol, 1.7220 g) or sulfathiazole (10 mmol, 2.5552 g). A few drops of acetic acid were added as a catalyst. The reaction mixture was refluxed with continuous stirring for 5–8 h in a water bath. The colored Schiff bases were filtered off, washed by ethanol and ether then dried in a calcium chloride desiccator. Recrystallization of the resulted solids was performed in hot ethanol–water solvents (1:1) for complete purification. The synthesized sulfanamide–Schiff bases are presented in Fig. 1. The IUPAC names of the synthesized ligands are N-(5-(5-Bromo-2-hydroxybenzylidene)amino)-benzenesulphonamide (SB$_1$), N-(5-(5-Bromo-2-hydroxybenzylidene)amino)N-(1,3-
thiazol-2-yl)benzenesulfonamide (SB2), 4-((3,5-Dibromo-2-hydroxybenzylidene)amino)-benzenesulfonamide (SB3), 4-((3,5-Dibromo-2-hydroxybenzylidene)amino)-N-(1,3-thiazol-2-yl)benzenesulfonamide (SB4), and 4-((3,5-Diiodo-2-hydroxybenzylidene)amino)-N-(1,3-thiazol-2-yl)benzenesulfonamide (SB5).

### Synthesis of nickel (II) complexes.

Ni (II) complexes were prepared by mixing an aqueous solution of Ni(NO₃)₂.6H₂O (1.4533 g, 5 mmol) with hot ethanolic solution of Schiff bases (SB1–SB5) (10 mmol) under stirring and reflux at 70 °C for 2 h. The solution was turned to a slightly basic medium (pH ≈ 8) by adding a few drops of ammonia (1:1). The yielded complexes were filtered, washed with a small amount of ethanol and ether, then kept in desiccators for drying. Elemental analysis and some physical properties of the synthesized ligands and their complexes are specified in Table 1.

![Systematic path for the synthesis of sulfonamide-Schiff base ligands (SB1–SB5).](image)

**Table 1.** Elemental analysis and physical properties of the synthesized nickel (II) complexes. All complexes have m.p. > 300 °C.

| Compound | Formula Color, m.p. °C | % Calculated/(Found) | μₑffective B.M | Geometry |
|----------|------------------------|----------------------|----------------|----------|
| SB1      | C₁₃H₁₁BrN₂O₃S Orange, 184–186 | – 43.96 (44.12) 3.12 (3.32) 7.89 (7.96) 9.03 (8.82) – – | – | – |
| [Ni(SB1−H)(SB1)]·2H₂O | C₃₉H₃₅Br₃N₆O₁₁S₃Ni Yellow | 5.07 (4.89) 40.44 (40.62) 3.05 (3.15) 7.26 (7.43) 8.30 (8.22) 3.13 Oh | – | – |
| SB2      | C₁₆H₁₂BrN₃O₃S₂ Yellow, 162–164 | – 43.84 (43.97) 2.76 (2.89) 9.59 (9.73) 14.63 (14.32) – | – | – |
| [Ni(SB2−H)(SB2)]·3H₂O | C₃₂H₂₈Br₂N₆O₉S₄Ni Greenish yellow | 5.94 (5.84) 38.93 (39.05) 2.86 (3.01) 8.51 (8.82) 12.99 (12.81) dia | – | – |
| SB3      | C₁₃H₁₀Br₂N₂O₃S Red, 242–244 | – 35.97 (36.12) 2.32 (2.35) 6.45 (6.43) 7.39 (7.22) – | – | – |
| [Ni(SB3−H)(OH)(H₂O)] | C₁₃H₁₂Br₂N₂O₅SNi Yellowish green | 11.14 (11.02) 29.64 (29.71) 2.30 (2.62) 5.32 (5.59) 6.09 (5.98) 0.50 SP | – | – |
| SB4      | C₁₆H₁₁Br₂N₃O₃S₂ Buff, 141–142 | – 37.16 (37.42) 2.14 (2.35) 8.12 (8.41) 12.40 (12.22) – | – | – |
| [Ni(SB4−H)(SB4)]·4H₂O | C₃₂H₂₈Br₄N₆O₁₀S₄Ni Greenish yellow | 5.05 (4.88) 33.04 (33.29) 2.43 (2.56) 7.23 (7.42) 11.03 (10.92) 2.91 Td | – | – |
| SB5      | C₁₆H₁₁I₂N₃O₃S₂ Brown, 243–245 | – 31.44 (31.62) 1.81 (2.15) 6.87 (7.10) 10.49 (10.22) – | – | – |
| [Ni(SB5−H)(OH)(H₂O)] | C₁₆H₁₃I₂N₃O₅S₂Ni Yellowish green | 8.34 (8.55) 27.30 (27.47) 1.86 (2.06) 5.97 (6.22) 9.11 (9.04) 2.15 SP ↔ Td | – | – |

**Figure 1.** Systematic path for the synthesis of sulfonamide-Schiff base ligands (SB1–SB5).
Results and discussion

FT-IR, NMR, and MS spectroscopy. Some fundamental FT-IR bands of the free ligands (SB1–SB5) and the synthesized Ni(II) complexes are compared in their position and shape as presented in Table S1 and illustrated in Figs. 1 and S1–S6. It is discernible from the spectral data that the assigned bands for the νCH=N and νC–O in the free ligands at 1599–1584 cm⁻¹ and 1232–1279 cm⁻¹, respectively, both suffer a lowering in intensity and wavenumbers supporting the bidentate coordination mode towards the Ni(II) through the phenolic oxygen and the nitrogen atom of the azomethine group (Fig. 2)15.

In the case of SB1 and SB2 ligands derived from sulfonamide moiety, typical adjacent bands of asymmetric and symmetric νN–H, were observed at 3314–3359 cm⁻¹ and 3232–3270 cm⁻¹, successively. Also, two stretching bands of the SO₂ group of these ligands were detected in 1318–1336 cm⁻¹ and 1138–1157 cm⁻¹ for the asymmetric and symmetric vibrational modes, respectively. No change in the band's position of NH₂, or SO₂ was discerned upon complexation which excludes these groups from being involved in the binding mode with the central metal ion. As for the ligands derived from sulfathiazole (SB3, SB4, and SB5), the inference of the exact change in position or the disappearance of the νO–H band of the phenolic group upon complexation was not straightforward due to overlapping with the νN–H band in the spectral region (3053–3457 cm⁻¹) as depicted in Table S1. However, some remarkable changes in this spectral region were spotted. For example, the broad feature in this region could be attributed to intramolecular hydrogen-bonding (O–H–N) with the nearby azomethine group in ligands or of (O–H–O) type with water molecules inside or outside the coordination sphere35. In addition, the new broad bands assigned for νO–H at ~3440 cm⁻¹ in the IR spectra of [Ni(SB3–H)(OH)(H₂O)] and [Ni(SB5–H)(OH)(H₂O)] complexes, Fig. 3, could endorse the existence of covalently bonded OH group in their inner spheres from the alkaline medium as previously reported36. Furthermore, the isolated complexes showed extra vibrational bands in the ranges 506–566 cm⁻¹ and 458–506 cm⁻¹, where these developed bands were assigned to the Ni–O and Ni–N stretching modes, respectively, indicating the proposed chelation mode35.

1H NMR and 13C NMR are additional techniques that support plentifully the structure elucidation of the synthesized compounds. The NMR data are collected in Figs. 4 and S7–S15 in the supplementary information with detailed assignments on each designated structure. Regarding the fundamental 1H NMR peaks, the phenolic OH at δ 12.53–14.26 ppm. This peak at δ 12.80 ppm in SB2 vanishes in the diamagnetic complex [Ni(SB2–H)₂] (Fig. 4) favoring the OH deprotonation prior to the chelation with Ni(II) ion. The presence of halogen atoms (Br or Cl) at positions C(3) and/or C(5) (Fig. 1) with an electron-withdrawing feature may facilitate the proton elimination at C(2). However, the NH peak of the sulfathiazole moiety in SB2, SB4, and SB5 which appeared at δ 12.52–12.84 ppm exhibits no change upon complexation. Also, the two protons of the sulfanilamide NH₂ group of SB1 and SB3 were observed in the aromatic region at δ 7.42 and 7.38 ppm, respectively. Moreover, Schiff base formation was further supported by the spotted azomethine proton (C7(H) = N) as a singlet peak in the range δ 8.86–9.01 ppm. Pertain to 13C NMR, the compound SB3, C₁₆H₁₂N₃O₃S₂Br, showed 14 different carbon peaks of which two possess integration corresponding to 2 identical carbons at 122.1 and 127.2 ppm for [C(9), C(13)] and [C(10), C(12)], respectively. Further, the position of halogen-bearing carbons [C(3) and C(5)] is clearly downfield shifted ongoing from SB3 (Fig. S13) to SB5 (Fig. S15) owing to the higher deshielding effect by Br atoms [C(3) 111.2; C(5) 112.4 ppm] relative to that induced by I atoms [C(3) 88.9; C(5) 82.1 ppm].

The structures of some selected ligands and complexes were further elucidated by the mass spectrometric technique. The mass-to-charge ratio (m/z) is displayed in Figs. 5, 6 and S16–S18, where the recorded molecular ion peaks are in accordance with the determined formula mass from the microanalytical technique. The m/z peaks at 987.59, 526.37, and 703.47 are assigned to the molecular weight of [Ni(SB3–H)₂]·3H₂O, [Ni(SB1–H) (OH)(H₂O)], and [Ni(SB5–H)(OH)(H₂O)] complexes, respectively. Besides, the peak with the highest intensity (100% abundance) that appeared at m/z 685.01 (Fig. S18) could be attributed to the corresponding fragment [Ni(SB5–H)(OH)]³⁺ with one water molecule less than its precursor. Moreover, the peak corresponding to the Ni isotope appeared clearly at m/z of ~ 59 in the mass spectra of the studied complexes (Figs. 6, S17, and S18).
Similarly, the molecular ion peaks are well in agreement with the molecular weight of the synthesized ligands (SB1 and SB2). Clearly, two molecular ion peaks of nearly equal intensity appeared at m/z of 354 and 356 for SB1 and m/z of 437 and 439 for SB2 respectively (Figs. S16 and S3). These twin molecular ion peaks represent [M − 1]+ and [M + 1]+ and appear due to bromine isotopes (79Br and 81Br)\(^{32}\). In addition, the base peak (100% intensity) of SB1 at m/z ~ 80 corresponds to the [SO2NH2] fragment of the sulfonamide group\(^{39}\). Also, the twin peaks that appeared at m/z 274 and 276 in the mass spectra of SB1 and SB2 is manifestly defining the cation [C13H9NOBr]+ (Fig. 7) which results from the elimination of the sulfonamide or sulfathiazole fragments in that order. The structural mass fragmentation pathways of SB2 ligand and [Ni(SB3–H)(OH)(H2O)] complex are represented in Figs. 7 and 8.

**Electronic spectra, magnetic, and conductivity measurements.** UV–Vis absorption spectra of the synthesized compounds were measured in the range 200–700 nm in DMF solvent. Two distinct absorption bands were observed within the ranges 265–292 and 326–367 nm attributed to the \(\pi\rightarrow\pi^*\) and \(n\rightarrow\pi^*\) transitions, respectively (Fig. 9). These bands are owing to the presence of OH, azomethine, and sulfonyl groups in the vicinity of the conjugated system. Similarly, these bands have appeared in the spectra of the Ni(II) complexes in the same wavelength ranges whereas obvious broadband in the region 415–454 nm is ascribed to the charge transfer of the type LMCT. This broad CT band in the absorbance spectra of the complexes completely obscured the expected d-d transitions in this region\(^{40}\).

The synthesized complexes possess a neutral non-electrolytic feature. This was verified by the low measured molar conductance of \(\Lambda_m < 4.5 \text{ } \Omega^{-1} \text{ } \text{mol}^{-1} \text{ } \text{cm}^2\) for a concentration of \(10^{-3} \text{ M}\) in DMF\(^{39}\). Additionally, different geometries of Ni (II) complexes were confirmed by the effective magnetic moments (\(\mu_{\text{eff}}\)) at room temperature (Table 1). Commonly, the diamagnetic behavior coincides with square planar geometry as in the case of

![Figure 3. FT-IR of (a) SB1, (b) [Ni(SB3–H)(OH)(H2O)], (c) SB5, (d) [Ni(SB5–H)(OH)(H2O)].](image-url)
[Ni(SB^2–H)2]·3H_2O complex. Also, [Ni(SB^1–H)2(SB^1)]·2H_2O that exhibited magnetic moments of 3.13 was assigned to octahedral geometry and consistent with the 1:3 (M:L) stoichiometry. However, the relatively low spin values within the range 0.5–2.91 B.M of the Ni(II) complexes derived from SB^3, SB^4, and SB^5 may be caused either by spin–spin interaction or tetrahedral ↔ square planar configurational equilibrium. The tetrahedral percentage can be calculated by the following mathematical formula:

\[ N_t = \frac{(\mu_{obs})^2}{(3.3)^2} \times 100 \]

where \( N_t \) is the tetrahedral percentage in the solid-state of the 4-coordinate complex and \( \mu_{obs} \) is the measured magnetic moment at 296 K. The calculated \( N_t \) for [Ni(SB^4–H)(OH)(H_2O)] was found to be 2.3% which indicates the dominance of the square planar configuration. Nevertheless, \( N_t \) values for [Ni(SB^3–H)2]·4H_2O and [Ni(SB^5–H)(OH)(H_2O)] were 77.8 and 42.4%, respectively.

Thermal analysis. The thermal stability of the synthesized nickel complexes was studied by TGA and DTA approaches in the temperature range up to 700 °C in a nitrogen atmosphere, Table 2 and Figs. 10 & S19. The main thermal decomposition stage of breaking the metal–ligand bonds starts in the temperature range 299.1–423.9 °C implying their thermal stability. This stage is preceded by the removal of small molecules such as hydrated H_2O, coordinated H_2O, NH_3, or SO_2. As an example, the thermal breakdown of [Ni(SB^4–H)]·4H_2O complex proceeds in three successive steps. The first step with a percentage mass loss of 6.32% (calc. 6.20%) was assigned to the removal of four outer sphere water molecules. This step was followed by the elimination of inner sphere small molecules (2 NH_3 and 2 SO_2) which started at the temperature of 220.4 °C. The decomposition of the bulk

Figure 4. ¹H NMR spectra of (a) SB^2, (b) [Ni(SB^2–H)2] complex in DMSO-d_6.
of two ligand molecules \((C_{32}H_{14}N_{4}OS_{2}Br_{4})\) begins at 347.0 °C with a DTA peak maximum \((T_{\text{max}})\) at 531.1 °C. The elevated \(T_{\text{max}}\) for this step is an indication of the complex thermal stability\(^{44}\). For all complexes, the thermal decomposition ended with the formation of NiO residue with a mass percentage in the range of 6.42% to 14.18%. Noteworthy, the combination of the decomposed fragments is in accord with the proposed structure of a given complex as deduced from spectroscopic and analytical data. However, the common overlap in the steps of the thermal decomposition could explain the slight variation between the calculated and found masses of the yielded thermal fragments.

**Molecular modeling study.** *Structural optimization and reactivity descriptors.* Molecular parameters of all synthesized ligands and Ni(II) complex of SB\(^3\) including frontier eigenvalues, dipole moments, bond lengths, and angles were calculated using DFT with B3LYP function and Lanl2dz basis set (Table 3 and Figs. 11, 12 &
S20–S25). The chemical reactivity of the synthesized Schiff bases was predicted from the energy difference between the low unoccupied (LUMO) and the high occupied molecular orbitals (HOMO) of the corresponding ligand, \( E \) (Fig. 13). Noticeably, there is a good correlation between the structure of synthesized ligands and their reactivity. For example, the sulfathiazole Schiff bases, SB2, and SB4 showed nearly similar \( E \) values within the range 3.466–3.487 eV. Also, the sulfonamide Schiff bases, SB1 and SB3 exhibited analogous \( E \) of 3.553–3.611 eV which implies parallel reactivity of these Schiff bases and indicates the existence of structural-activity relation among the ligands. Based on the optimization parameters, the halogen substituents induce extra stability of the LUMO levels. This can be predicted by the higher negative total energy, \( E_T \), of the di-halogenated ligands (SB3, SB4, and SB5) compared to the mono-halogenated ligands (SB1 and SB2) (Table 3). Moreover, the iodide substituents gave more induced LUMO level stability than the bromide substituents due to the relatively large size of iodide and hence increases the electrophilic character. Furthermore, the high negative total energy of the complex \([\text{Ni(SB5–H)}(\text{OH})(\text{H}_2\text{O})]\), \( E_T = \) −1370 Hartree, indicates the great stability of the isolated complex compared to its free ligand. Besides, the distortion of the standard square planar geometry of the complex \( \text{Ni(II)}–\text{SB5} \) (1:1) was estimated from the calculated bond angles around the Ni(II) core which are consistent with the determined tetrahedral percentage (\( N_t \), 42.4%) from the experimental magnetism value. The estimated angles N(12)–Ni(34)–O(9), O(9)–Ni(34)–O(36), O(36)–Ni(34)–O(35), and O(35)–Ni(34)–N(12) of Ni(II)–SB5 complex were 95.38°, 87.47°, 78.36°, and 98.97°, respectively representing a mixture of square planar and tetrahedral geometries around the central Ni (II) ion (Table S2 and Fig. 14). Additionally, it was observed that the bonds between the atoms incorporated in the coordination sphere (C(4)–O(9) and C(10)=N(12)) showed longer lengths in the complex than in the free ligand (Table S2). However, no change in the bond lengths was noted in the sulfonamide or sulfathiazole parts after the complex formation excluding them from any expected coordination. The magnitude of the calculated dipole moment (\( D \)) gives a good indication of the capability of

Figure 7. Proposed mass fragmentation SB2 ligand.
the compound to penetrate the biological cell membrane. Generally, the lower the dipole moment, the higher the penetration strength across the phospholipid bilayer\(^4\). In addition, based on the other calculated molecular descriptors; softness \((S)\), hardness \((\eta)\), electrophilicity \((\omega)\), and electronegativity \((\chi)\), the estimated chemical reactivity of the ligands toward metal ions or any neighboring biological receptors is in the order: \(SB^2 > SB^5\)

Figure 8. Proposed mass fragmentation of \([Ni(SB^3−H)(OH)(H_2O)]\) complex.

Figure 9. UV–Vis absorption band of \(SB^3\) and \(SB^5\) ligands and their complexes.
SB2 > SB3 > SB1, where 4 SB5 is proposed to have the highest softness character (S = 0.300 eV⁻¹) and the smallest E, i.e. the highest electron donation ability. Furthermore, the electron density cloud was mapped over the surface of the ligands to evaluate the nucleophilic (high electron density, red) and the electrophilic (low electron density, blue) sites of interactions (Figs. 14 and S25)⁴⁹. The regions with zero electronic potential are denoted by green. For all ligands, the (SO2) group represents the site with intense electron density, while there is a lack of electron density at the hydrogen terminals. Nevertheless, the N(13) of the azomethine and O(9) of the phenol parts of SB5 (Fig. 14) showed moderate nucleophilicity with Mulliken charges of −0.587 and −0.596 a.u. for N(13) and O(9) respectively, and hence can be possible electron donor atoms in the coordination mode as proposed spectroscopically.

| Complex (M:L) | Tmax °C | Temp. Range (°C) | Wt. loss / Residue % | Assignment |
|---------------|--------|-----------------|---------------------|------------|
| [Ni(SB1)₂(SB1–H)]·2H₂O (1:3) | 132.6 | 31.0–230.0 | 5.86 6.05 | -2H₂O, -2NH₃ |
| | 313.9 | 230.0–377.4 | 16.43 16.59 | -3SO₂ |
| | 436.8 | 377.5–695.8 | 71.28 70.91 | -C₃₉H₂₅O₂N₄Br₃ |
| Residue | 6.43 | 6.45 | NiO |
| [Ni(SB²)₂·3H₂O (1:2)] | 185.4 | 34.9–265.4 | 9.24 8.92 | -3H₂O, -2NH₃ |
| | 305.4 | 265.4–389.2 | 12.71 12.98 | -2SO₂ |
| | 446.2 | 389.2–697.8 | 70.58 70.53 | -C₃₂H₁₆N₄OS₂Br₂ |
| Residue | 7.47 | 7.56 | NiO |
| [Ni(SB³–H)(OH)(H₂O)] (1:1) | 143.6 | 35.3–201.3 | 6.79 6.84 | -2H₂O |
| | 374.5 | 304.6–423.9 | 15.52 15.39 | -NH₃, -SO₂ |
| | 517.5 | 423.9–698.6 | 63.78 63.59 | -C₁₃H₅NBr₂ |
| Residue | 13.91 | 14.18 | NiO |
| [Ni(SB⁴–H)₂·4H₂O (1:2)] | 151.9 | 28.3–220.4 | 6.32 6.20 | -4H₂O |
| | 320.1 | 220.4–347.0 | 13.96 13.94 | -2NH₃, -2SO₂ |
| | 531.1 | 347.0–698.3 | 73.32 74.44 | -C₃₂H₁₄N₄OS₂Br₄ |
| Residue | 6.40 | 6.42 | NiO |
| [Ni(SB⁵–H)(OH)(H₂O)] (1:1) | 96.6 | 39.7–160.3 | 5.04 5.12 | -2H₂O |
| | 236.4 | 160.3–299.1 | 11.36 11.52 | -NH₃, -SO₂ |
| | 327.2 | 299.1–698.6 | 73.20 72.75 | -C₁₆H₆N₂SI₂ |
| Residue | 10.40 | 10.61 | NiO |

Table 2. Thermogravimetric decomposition steps of Ni(II) complexes derived from SB¹–SB⁵.

Figure 10. TGA of the Ni(II)-Schiff base complexes under N₂ atmosphere.

SB² > SB³ > SB¹, where ⁴ SB⁵ is proposed to have the highest softness character (S = 0.300 eV⁻¹) and the smallest E, i.e. the highest electron donation ability.

Furthermore, the electron density cloud was mapped over the surface of the ligands to evaluate the nucleophilic (high electron density, red) and the electrophilic (low electron density, blue) sites of interactions (Figs. 14 and S25)⁴⁹. The regions with zero electronic potential are denoted by green. For all ligands, the (SO2) group represents the site with intense electron density, while there is a lack of electron density at the hydrogen terminals. Nevertheless, the N(13) of the azomethine and O(9) of the phenol parts of SB⁵ (Fig. 14) showed moderate nucleophilicity with Mulliken charges of −0.587 and −0.596 a.u. for N(13) and O(9) respectively, and hence can be possible electron donor atoms in the coordination mode as proposed spectroscopically.
Molecular docking. Docking investigation is an essential step preceding the in vitro study of any proposed biologically active compound. This approach elucidates the ligand-receptor site and type of interactions. It also gives an estimation of the distance between the ligand and the receptor inside the interaction grid. The scoring energy of each pose simulated by the docking calculations reflects the degree of inhibition effect of the corresponding ligand. In the present study, the selected protein 3s7s represents the crystal structure of the human placental aromatase enzyme that catalyzes the synthesis of estrogen hormone and contributes to estrogen-dependent breast cancer. All ligands possess an appreciable extent of interactions with the receptor protein based on the scoring energy (S), the number, and the length of H-bonds (Table 4 and Figs. 15 & S26). Favorable interaction was discerned for SB5 with many bonds formed inside the protein binding pocket and high scoring energy of (−8.6219 kcal/mol). The great number of H-bonds would successfully facilitate its penetration across the cell membrane.

Also, the ligands SB4 and SB2 exhibited reasonable interaction with the target protein with scoring energies of −8.9932 and −8.3594 kcal/mol, respectively, indicating their high binding affinity with the receptor protein. Effectively short H-bond was observed in most of the docked protein–ligand complexes. As an example, the interaction of SB1 and SB4 through O(27) with ARG 115 amino acid and O(9) with ARG 435 amino acid respectively, displayed bond lengths that are less than 3.5 Å. Worth mentioning that the negative values of the binding energies (Table 4) indicate spontaneous interaction with the protein. Moreover, a number of halogen bonds were observed between ligands and some receptor sites inside the protein pocket (Figs. 15 and S26). However, these multiple weak bonds boost the inhibition impact of the ligands. Docking parameters against the protein 3s7s were also evaluated for a standard sulfa drug Trimethoprim-sulfamethoxazole (Bactrim). The drug contains a sulfamethoxazole moiety that resembles the synthesized ligands. The drug showed less scoring energy, Table 4 and Fig. S27, than the synthesized Schiff bases, implying high inhibition activity for the ligands SB1–SB5.

Biological activity assessment. Antimicrobial potency study. The biological activity data of all ligands (SB1–SB5) and some selected complexes are summarized in Table 5 and Fig. 16. The observed mean zone diameter of inhibition in mm is considered a good index of the antimicrobial activity of the tested samples. For most of the studied strains, ligands show more inhibition efficacy than their corresponding complexes. However, a plau-
Possible comparative study of the antimicrobial potency of the compounds under investigation was achieved based on their minimum inhibitory concentration values in μM rather than µg/ml owing to their different molecular weights and according to the microdilution broth assay. Among the ligands, SB4 showed superior broad-spectrum activity in prohibiting microbial growth that is sometimes matching or even better than that of the utilized references. For instance, *B. subtilis*, *E. coli*, and *A. fumigatus* strains were very sensitive to SB4 with MIC values of 0.46, 7.54, and 0.95 μM, respectively, which are lower than that displayed by ampicillin (1.40 μM), gentamycin (8.38 μM), and ketoconazole (1.88 μM) as reference controls. In general, it is difficult to deduce a certain conclusion relating the observed activity with the skeleton of such compounds that contain diverse bioactive moieties such as benzenesulfonamide or salicylaldehyde imine including hydroxyl group, halogens, or heteroatomic thia-

---

**Figure 12.** The optimized structure of [Ni(SB5–H)(OH)(H2O)] complex using DFT-B3LYP Lanl2dz method by GAUSSIAN 09 software version 9.5 and GAUSSVIEW 6.0.16.

**Figure 13.** LUMO and HOMO of SB5 and [Ni(SB5–H)(OH)(H2O)] complex, using GAUSSIAN 09 software version 9.5 and GAUSSVIEW 6.0.16.
zole ring, (Fig. 1). Notwithstanding such difficulty, the superior potency of the Schiff base ligand (SB4) could be credited to the consortium of different bioactive substituents as two bromine atoms and a thiazole ring attached to the Schiff base backbone structure. The two bromine substituents probably enhance the inhibitory effect of the attached system by their electron-withdrawing property as reported for analogous Schiff base compounds52,53. This is in harmony with the spotted decrease in the activity of SB1 or SB2 (mono-brominated Schiff bases), and SB3 (absence of thiazole ring) in comparison with SB4. Also, the substituent size (I or Br) is a crucial factor in determining the feasibility of pathogen inhibition54,55. Noticeably, the Gram-negative P. vulgaris bacteria showed the least susceptible character against most tested compounds (Table 5) pointing to the importance of its outer lipid membrane as an additional shield despite its thinner peptidoglycan wall56.

Figure 14. Molecular electrostatic potential map of SB5, using GAUSSIAN 09 software version 9.5 and GAUSSVIEW 6.0.16.

| Compound | Ligand site | Receptor site | Interaction type | Distance (Å) | E (kcal/mol) | S (kcal/mol) |
|----------|-------------|---------------|-----------------|--------------|--------------|--------------|
| SB1      | N 28        | PHE 430       | H-donor         | 3.28         | − 0.7        | − 6.6717     |
|          | N 28        | ARG 435       | H-donor         | 3.33         | − 1.2        |              |
|          | Br 31       | MET 447       | Halogen bonding | 4.31         | − 0.4        |              |
|          | O 27        | ARG 115       | H-acceptor      | 2.81         | − 1.8        |              |
| SB1      | S 31        | MET 303       | H-donor         | 3.94         | − 0.2        | − 8.3594     |
|          | Br 37       | ARG 435       | Halogen bonding | 3.32         | − 0.8        |              |
|          | O 27        | ALA 307       | H-acceptor      | 3.20         | − 0.8        |              |
| SB1      | O 9         | MET 311       | H-donor         | 3.17         | − 1.9        | − 7.1499     |
|          | N 27        | GLU 302       | H-donor         | 3.28         | − 1.4        |              |
|          | N 27        | MET 303       | H-donor         | 3.70         | − 3.1        |              |
|          | Br 30       | PRO 429       | Halogen bonding | 3.04         | − 0.5        |              |
|          | Br 31       | MET 447       | Halogen bonding | 3.52         | − 0.4        |              |
|          | 6-ring      | ALA 306       | π-H             | 3.73         | − 0.7        |              |
| SB4      | O 9         | ARG 435       | H-donor         | 2.99         | − 2.2        | − 8.9932     |
|          | Br 37       | ARG 375       | Halogen bonding | 3.31         | − 1.0        |              |
| SB4      | O 9         | MET 311       | H-donor         | 3.40         | − 1.2        | − 8.6219     |
|          | S 30        | ARG 435       | H-donor         | 3.87         | − 0.9        |              |
|          | I 37        | MET 447       | Halogen bonding | 3.99         | − 0.8        |              |
|          | O 26        | ARG 115       | H-acceptor      | 3.50         | − 0.6        |              |
| [Ni(SB3-H)(OH)(H2O)] | O 9  | MET 311 | H-donor | 3.76 | − 1.1 | − 8.5098 |
|          | I 37        | MET 447       | Halogen bonding | 4.10         | − 1.0        |              |
| Sulfa-methoxazole moiety of standard drug | N 15 | LEU 372 | H-donor | 3.24 | − 1.1 | − 6.2313 |
|          | O 13        | MET 374       | H-acceptor      | 3.08         | − 1.6        |              |

Table 4. The interaction parameters of the synthesized compounds versus 3s7s protein.
The antiproliferative potency. The concentration of some selected synthesized compounds as anticancer candidates to inhibit the growth of the proliferative cells by 50% (IC$_{50}$) in μM was evaluated against MCF-7 (human breast cancer cell line). All ligands and some of their nickel complexes showed appreciable cytotoxicity against MCF-7 (Table 6 and Figs. 17 & S28), compared to cisplatin as a chemotherapy standard drug for breast cancer. Based on the IC$_{50}$ values, both SB$_2$ (16.0 μM) and SB$_4$ (18.8 μM) have nearly equipotent antiproliferative activity as cisplatin (19.0 μM) against MCF-7 cells and both are more active than SB$_1$ (28.2 μM) and SB$_3$ (29.7 μM) (Table 6). This variety in IC$_{50}$ values points to the importance of the existence of the thiazole moiety and Br atom(s) in the building structure of the Schiff base ligands (SB$_2$ and SB$_4$) (Fig. 1) as deduced in the antimicrobial Sect. 8.55. Interestingly, SB$_5$ (6.32 μM) exhibited threefold inhibition efficacy more than cisplatin recommending it as a promising breast anticancer drug and in accord with US NCI program (IC$_{50} < 10$ μM)$^{57}$. A similar cytotoxicity tendency was observed for complexes where [Ni(SB$_2$–H)$_2$]·3H$_2$O (11.2 μM) and [Ni(SB$_4$–H)$_2$]·4H$_2$O (4.33 μM) have nearly twofold or fourfold potency in comparison with cisplatin against the human MCF-7 cell lines. The double cytotoxicity of Ni(SB$_4$–H)$_2$]·4H$_2$O could be related to the presence of two additional Br atoms than the case of [Ni(SB$_2$–H)$_2$]·3H$_2$O complex as both complexes have the same 4-coordinate geometry, metal to ligand ratio (1:2), and the same bioactive functional groups (benzenesulfonamide, thiazole, and salicylaldehyde imine). Unlike the SB$_5$ ligand, [Ni(SB$_5$–H)(OH)(H$_2$O)] complex (1:1) has insignificant activity against MCF-7 cells where the chelation suppresses the antiproliferation in this case as discerned from the docking simulation.

Figure 15. Ligand-receptor interactions of SB$_5$ and its Ni(II) complex versus 3s7s protein, using the Molecular Operating Environmental module (MOE 2015.10) software.
Furthermore, a comparative study was also made to compare the cytotoxicity of some ligands (SB1 and SB2) against different human cell lines HCT-116 (colon carcinoma), HepG-2 (hepatocellular carcinoma), and MCF-7 (breast carcinoma) (Figs. 18, 19). The investigated ligands SB1 and SB2 exhibited the same trend of cytotoxicity where the best inhibitory activity was observed against HCT-116 (IC50 12.4 and 12.3 μM) and the least was against HepG-2 (IC50 33.8 and 21.7 μM), respectively. Noteworthy, SB4 and all Ni (II) complexes exhibited less cytotoxic activity against the human normal oral epithelial cell, OEC, compared to cisplatin Table 6 and Fig. S29.

Conclusion
In the current investigation, five new nickel complexes of halogenated sulfonamide-based Schiff bases (SB1–SB5) were synthesized and structurally explored by microanalytical analyses, FT-IR, NMR, UV–Vis., MS, and thermal analysis techniques. Spectral studies supported the bidentate coordination mode of all ligands towards the Ni(II) through the phenolic oxygen after deprotonation and the nitrogen atom of the azomethine group. The magnetic data revealed that the geometries of complexes are octahedral, square planar, or tetrahedral. The recorded

Table 5. Antibacterial and antifungal inhibition zone in mm and the MIC (µM) of the Schiff bases and some of their complexes. NA: no activity, NT: not tested.

| Compound                  | Gram-positive bacteria | Gram-negative bacteria | Fungi          |
|---------------------------|------------------------|------------------------|----------------|
|                           | S. aureus              | B. subtilis            | P. vulgaris   | E. coli | A. fumigatus | C. albicans |
|                           | 14.6 ± 0.4 (351.9)     | 16.2 ± 0.5 (176.0)     | NA            | 13.7 ± 0.3 (> 1000) | 15.2 ± 0.4 (176.0) | NA |
| SB2                       | 16.0 ± 0.4 (142.6)     | 18.3 ± 0.6 (357.7)     | NA            | 13.0 ± 0.4 (> 1000) | 16.5 ± 0.6 (142.6) | NA |
| SB3                       | 15.0 ± 0.5 (719.9)     | 23.0 ± 0.8 (719.9)     | 22.0 ± 0.7 (> 1000) | 24.0 ± 0.6 (> 1000) | 40.0 ± 0.9 (339.9) | 22.0 ± 0.7 (719.9) |
| SB4                       | 20.6 ± 0.4 (7.54)      | 24.0 ± 0.7 (0.46)      | NA            | 19.8 ± 0.5 (7.54)  | 23.4 ± 0.6 (0.95)  | NA |
| SB5                       | 13.0 ± 0.3 (> 1000)    | 20.0 ± 0.7 (511.3)     | 12.0 ± 0.6 (> 1000) | NA     | 22.0 ± 0.7 (511.3) | 15.0 ± 0.5 (255.6) |
| [Ni(SB4–H)2]·4H2O         | 15.0 ± 0.6 (> 1000)    | 20.0 ± 0.8 (537.3)     | 15.0 ± 0.5 (> 1000) | 12.0 ± 0.4 (> 1000) | 28.0 ± 0.9 (537.3) | 15.0 ± 0.6 (268.7) |
| [Ni(SB5–H)(OH)(H2O)]      | 10.0 ± 0.4 (> 1000)    | 15.0 ± 0.6 (88.8)      | 18.0 ± 0.7 (> 1000) | 17.0 ± 0.7 (88.8)  | 20.0 ± 0.9 (> 1000) | 19.0 ± 0.8 (> 1000) |
| Ampicillin                | 23.7 ± 0.6 (2.85)      | 26.4 ± 0.5 (1.40)      | NT            | NT    | NT          | NT         |
| Gentamycin                | NT                     | NT                     | 25.0 ± 0.3 (8.38) | 30.0 ± 0.4 (8.38) | NT   | NT         |
| Ketoconazole              | NT                     | NT                     | NT            | NT    | 17.1 ± 0.3 (1.88) | 20.2 ± 0.4 (1.88) |

Figure 16. Inhibition zone (mm) of the synthesized compounds against selected microbes.
Table 6. Cytotoxicity activity (IC₅₀) in μg/ml and µM of Schiff bases and some of their complexes.

| Compounds                  | MCF-7 μg/ml | OEC μg/ml | OEC µM |
|----------------------------|-------------|-----------|--------|
| SB³                        | 10.0 ± 0.9  | 28.2 ± 1.9| NT     |
| SB¹                        | 7.0 ± 0.6   | 16.0 ± 1.2| NT     |
| SB⁵                        | 12.9 ± 1.2  | 29.7 ± 1.8| NT     |
| SB¹                        | 9.73 ± 1.0  | 18.8 ± 1.3| 49.53 ± 1.95|
| SB¹                        | 3.86 ± 0.5  | 6.32 ± 0.8| NT     |
| [Ni(SB²–H)₂]·3H₂O         | 11.3 ± 1.1  | 11.2 ± 0.9| 62.23 ± 3.11|
| [Ni(SB⁴–H)₂]·4H₂O         | 5.04 ± 0.6  | 4.33 ± 0.5| 33.59 ± 1.68|
| [Ni(SB⁵–H)(OH)(H₂O)]     | 365 ± 24.6  | > 100     | > 100  |
| Cisplatin                  | 5.71 ± 0.7  | 19.0 ± 2.3| 32.68 ± 2.74|

Figure 17. Inhibitory activity of the synthesized ligands against breast carcinoma cells MCF-7.

Figure 18. The inhibitory dose curves of SB¹ against three cell lines HepG-2, MCF-7, and HCT-116.
molecular ion peaks (m/z) are in accordance with the determined formula mass from the microanalytical technique. The molecular descriptor parameters calculated by DFT-B3LYP/Lanl2dz and the molecular docking simulation with the breast cancer protein (3s7s) approved the structural-activity relationship of the investigated compounds. SB² showed the most significant inhibition activity towards some pathogen strains (B. subtilis, E. coli, and A. fumigatus) which is attributed to the presence of two electron-withdrawing bromine atoms in the salicylidene moiety and the attached thiazole ring to the bioactive benzenesulfonamide group. According to the IC₅₀ values, SB² and [Ni(SB²–H)₂]·4H₂O have nearly threefold or fourfold potency in comparison with cisplatin against breast carcinoma cells (MCF-7) recommending them as promising antiproliferative agents after further drug authorization processes. Ultimately, the nickel (II) complex derived from SB² is economically expected to be of less expense with respect to other chemotherapeutic platinum-based drugs.

**Data availability**

All data generated or analyzed during this study are included in this published article and its supplementary information files.

Received: 23 September 2022; Accepted: 16 November 2022
Published online: 23 November 2022

**References**

1. Hassan, M. A., Omer, A. M., Abbas, E., Baset, W. & Tamer, T. M. Preparation, physicochemical characterization, and antimicrobial activities of novel two phenolic chitosan Schiff base derivatives. Sci. Rep. 8, 11416. https://doi.org/10.1038/s41598-018-29650-w (2018).
2. Safdari, F., Raissi, H., Shahabi, M. & Zaboli, M. DFT calculations and molecular dynamics simulation study on the adsorption of 5-fluouracil anticancer drug on graphene oxide nanosheet as a drug delivery vehicle. J. Inorg. Organomet. Polym. Mater. 27, 805–817. https://doi.org/10.1007/s10904-017-0525-9 (2017).
3. Makhova, N. N. et al. Progress in the chemistry of nitrogen-, oxygen- and sulfur-containing heterocyclic systems. Russ. Chem. Rev. 89, 55–124. https://doi.org/10.1070/RCR4914 (2020).
4. Masoud, M. S., Soayed, A. A., Almesmari, S. A. & Elsamra, R. M. I. New mixed-ligand complexes of cytosine and its silver nanomolecules: Spectral, analytical, theoretical and biological activity studies. J. Inorg. Organomet. Polym. Mater. 31, 2842–2858. https://doi.org/10.1007/s10904-021-01945 (2021).
5. Amer, H. H. et al. Antibacterial and molecular docking studies of newly synthesized nucleosides and Schiff bases derivatives metal complexes. Inorg. Chem. Commun. 141, 109459. https://doi.org/10.1016/j.inoche.2022.109459 (2022).
6. Alamgir, M. et al. Amalgamation, scrutinizing, and biological evaluation of the antimicrobial aptitude of thiosemicarbazide Schiff bases derivatives metal complexes. Inorg. Chem. Commun. 141, 109459. https://doi.org/10.1016/j.inoche.2022.109459 (2022).
7. Mondal, S., Mondal, T. K., Rajesh, Y., Mandal, M. & Sinha, C. Copper (II)-sulfonamide Schiff base complexes: Structure, biological activity and theoretical interpretation. Polyhedron 151, 344–354. https://doi.org/10.1016/j.poly.2018.05.037 (2018).
8. Ramadan, A. M., Bayoumi, H. A. & Elsamra, R. M. I. Synthesis, characterization, biological evaluation, and molecular docking approach of nickel (II) complexes containing O, N-donor chelation pattern of sulfonamide-based Schiff bases. Appl. Organomet. Chem. 35, e6412. https://doi.org/10.1002/aoc.6412 (2021).
9. Griffith, E. C. et al. The structural and functional basis for recurring sulfa drug resistance mutations in Staphylococcus aureus dihydropteroate synthase. Front. Microbiol. 9, 1369. https://doi.org/10.3389/fmicb.2018.01369 (2018).
10. Muthukumar, R., Kannan, M., Elangovan, N., Karunanidhi, M. & Thomas, R. Synthesis, spectral analysis, antibacterial activity, quantum chemical studies and supporting molecular docking of Schiff base (E)-4-(4-bromobenzylidene) amino)benzenesulfonamidem. J. Indian Chem. Soc. 99, 100405. https://doi.org/10.1016/j.jics.2022.100405 (2022).
11. Nunes, P. et al. Copper (II) and oxidovanadium (IV) complexes of chromone Schiff bases as potential anticancer agents. J. Biol. Inorg. Chem. 27, 89–109. https://doi.org/10.1007/s00775-021-01913-4 (2022).
12. Parsekar, S. U. et al. DNA binding, cleavage and cytotoxicity studies of three mononuclear Cu (II) chloro–complexes containing N,S donor Schiff base ligands. J. Biol. Inorg. Chem. 23, 1331–1349. https://doi.org/10.1007/s00775-018-1620-2 (2018).
13. Kargar, H., Adabi Arakani, A., Munawar, K. S., Ashfaq, M. & Tahir, M. N. Nickel (II), copper (II) and zinc (II) complexes containing symmetrical Tetradentate Schiff base ligand derived from 3, 5-diodosalicylaldehyde: Synthesis, characterization, crystal structure and antimicrobial activity. J. Iran. Chem. Soc. 18, 2493–2503. https://doi.org/10.17650/jics.137381-021-02207-x (2021).

14. Elangovan, N., Gangadharpappa, B., Thomas, R. & Irfan, A. Synthesis of a versatile Schiff base 4-(2-hydroxy-3, 5-diiodobenzylidene) amino benzenesulphonamide from 3, 5-diodosalicylaldehyde and sulfanilamide, structure, electronic properties, biological activity prediction and experimental antimicrobial properties. J. Mol. Struct. 1250, 131700. https://doi.org/10.1016/j.molstruc.2021.131700 (2022).

15. Thakur, S., Gil, D. M., Frontera, A. & Chattopadhyay, S. Exploration of β-β-β-Halon bond interactions in dinuclear vanadium (V) complexes with Schiff base ligands. Polyhedron 187, 114676. https://doi.org/10.1016/j.poly.2021.114676 (2020).

16. Kordestani, N. et al. Copper (ii) complexes with tridentate halogen-substituted Schiff base ligands: Synthesis, crystal structures and investigating the effect of halogenation, leaving groups and ligand flexibility on antiproliferative activities. Dalton Trans. 50(11), 8490–8497. https://doi.org/10.1039/d0dt03962x (2021).

17. Daraie, M., Bagheri, D., Malmir, M. & Heravi, M. M. Investigation of halloysite nanotubes and Schiff base combination with deposited copper iodide nanoparticles as a novel heterogeneous catalytic system. Sci. Rep. 11, 23658. https://doi.org/10.1038/s41598-019-03277-0 (2021).

18. Behpour, M., Ghoreishi, S. M., Mohammadi, N., Soltani, N. & Salavati-Niasari, M. Investigation of some Schiff base compounds containing disulfide bond as HCl corrosion inhibitors for mild steel. Corros. Sci. 52, 4046–4057. https://doi.org/10.1016/j.corsci.2010.08.029 (2010).

19. Yousif, E., Hasan, A. & El-Hiti, G. A. Spectroscopic, physical and topography of photographic process of PVC films in the presence of Schiff base metal complexes. Polymers 8, 204. https://doi.org/10.3390/polym8060204 (2016).

20. Huang, X. F., Zhang, Y. B., Wang, X. L., Tang, J. F. & Ruan, B. F. Synthesis, characterization, and antimicrobial activities of a dinuclear copper (II) complex with bis (2-[2-hydroxy-ethylimino]-methyl)-4, 6-dioido-phenol). J. Coord. Chem. 63, 630–636. https://doi.org/10.1080/00958972.2011.552604 (2011).

21. El-Sonbati, A. Z. Synthesis, spectral, computational, wavefunction and molecular docking studies of 3-(thiophene-2-thyl methyl) amino benzenesulphonamide from sulfanilamide and thiophene-2-carbaldehyde. J. Iranian Chem. Soc. 9(10), 100718. https://doi.org/10.22077/jics.2022.100718 (2022).

22. Brewster, C. M. Schiff’s bases from 3, 5-dibromo-salicylaldehyde. J. Am. Chem. Soc. 46, 2463–2468. https://doi.org/10.1021/ja010616v (1924).

23. Xu, S. P., Shi, L., Lv, P. C., Fang, R. Q. & Zhu, H. L. Synthesis and antibacterial activities of metal (II) complexes with Schiff bases derived from 3, 5-diodosalicylaldehyde. J. Coord. Chem. 62, 2048–2057. https://doi.org/10.1080/00958972.2009.108095897002741521 (2009).

24. Jeffery, G. H., Bassett, J., Mendham, J. & Denney, R. C. Vogel’s Textbook of Quantitative Chemical Analysis ( Wiley, New York, 1989).

25. Frisch, M. J., Trucks, G. W., Schlegel, H. B., Scuseria, G. E., Robb, M. A., Cheeseman, J. R., Gaussian 09, Revision A.02, Gaussian Inc, Wallingford CT 34, Wallingford CT (2009).

26. Dennington, R. D., Keith, T. & Millam, J. GaussView, Version 4.1.2 (Semichem Inc., Shawnee Mission, KS, 2007).

27. Becke, A. D. A new mixing of Hartree-Fock and local density-functional theories. J. Chem. Phys. 98, 1372–1377. https://doi.org/10.1063/1.463400 (1993).

28. El-ghamry, M. A., Elzrawi, F. M., Aziz, A. A. A., Nassir, K. M. & Abu-El-Wafa, S. M. New Schiff base ligand and its novel Cr (III), Mn (II), Co (II), Ni (II), Cu (II), Zn (II) complexes: Spectral investigation, biological applications, and semiconducting properties. Sci. Rep. 12, 17942. https://doi.org/10.1038/s41598-022-22713-z (2022).

29. Biemer, J. J. Antimicrobial susceptibility testing by the Kirby-Bauer disc diffusion method. Ann. Clin. Lab. Sci. 3, 135–140 (1973).

30. Geggel, C., Simsek, U. B., Turabik, M. & Ozdemir, S. Synthesis of titanium doped iron based metal–organic frameworks and investigation of their biological activities. J. Inorg. Organomet. Polym. Mater. 30, 749–757. https://doi.org/10.1007/s10904-019-01329-3 (2020).

31. Ramadan, A. M., Elsamra, R. M. I. & Bondock, S. New pyrazole-4-carbothioamide-based metal complexes: Synthesis, spectral characterization, computational, antimicrobial, and antitumor investigations. J. Coord. Chem. 35, e6102. https://doi.org/10.1002/aoc.6102 (2021).

32. Al-Mutabagani, L. A. et al. Synthesis and biological evaluation of thiazolyl-ethyldiene hydrazino-thiazole derivatives: A novel heterocyclic system. Appl. Sci. 11, 8908. https://doi.org/10.3390/app1118908 (2021).

33. Nagpal, P. & Singh, R. V. Toxicological effects, biological aspects and spectral characterization of organoboron (III) complexes of sulfonamide-imines. Appl. Organomet. Chem. 18, 221–226. https://doi.org/10.1002/aoc.610 (2004).

34. Al-Awadi, N., Shaub, N. M. & El-Dissouky, A. A. Synthesis and spectroscopic characterization of nickel (II) complexes of 1-benzotriazol-1-yl-[pX-phenyl] hydrazone propan-2-one. Spectrochim. Acta A Mol. Biomol. Spectrosc. 65, 36–43. https://doi.org/10.1016/j.saa.2005.09.024 (2006).

35. Ramadan, A. M., Alshehri, A. A. & Bondock, S. Synthesis, physico-chemical studies and biological evaluation of new metal complexes with some pyrazolone derivatives. J. Saudi Chem. Soc. 23, 1192–1205. https://doi.org/10.1016/j.jscs.2019.08.001 (2019).

36. Kulandaisamy, A. et al. Halogen-Bonding 175-HSD1 Inhibitors: Insights from DFT, Docking, and Molecular Dynamics Simulation Studies. Molecules 27, 3962. https://doi.org/10.3390/molecules27123962 (2022).

37. Elsebach, M. et al. In situ synthesis of metal–salophene complexes on intercalated graphene. J. Phys. Chem. C 124, 4279–4287. https://doi.org/10.1021/acs.jpcc.9b06894 (2020).

38. Elsebach, M. et al. J. Phys. Chem. C 124, 4279–4287. https://doi.org/10.1021/acs.jpcc.9b06894 (2020).
Acknowledgements
The authors wish to convey their appreciation to Alexandria University, Alexandria, Egypt for offering technical and administrative support.

Author contributions
Author contributionRMI Elsamra, AM Ramadan, and MS Masoud contributed to the study design, RMI Elsamra and AM Ramadan performed the experiments and analysis of the data. RMI Elsamra and AM Ramadan contributed to the writing of the manuscript. All authors read and approved the final manuscript.

Funding
Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-24512-y.

Correspondence and requests for materials should be addressed to R.M.I.E.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022